Peripheral medulloepithelioma: A rare tumor with a potential target therapy

  • Pasquale M. D. De*
  • , Ioris M. A. De
  • , A. Gallo
  • , Angela Mastronuzzi
  • , A. Crocoli
  • , R. Cozza
  • , R. Boldrini
  • *Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo

Abstract

Background: Medulloepithelioma (ME) is a rare embryonal tumor predominantly located in the eye or in the central nervous system without an established treatment.Case presentation: We report of a case of a localized peripheral ME treated with conventional and high dose chemotherapy, surgery and local radiotherapy. At relapse, the tumor tissue revealed a different molecular signature compared to the initial tumor mass. This molecular signature revealed a high expression of platelet derived growth factor receptor (PDGFR). Sorafenib plus irinotecan and temozolomide was started with a 5 month progression free survival.Conclusion: Our experience suggests a possible role of sorafenib or different PDGFR inhibitors in ME. Targeting treatment could represent an adjuvant and/or alternative therapy for ME and other rare tumors. © 2014 De Pasquale et al.; licensee BioMed Central Ltd.
Lingua originaleInglese
pagine (da-a)1-6
Numero di pagine6
RivistaJournal of Translational Medicine
Volume12
Numero di pubblicazione1
DOI
Stato di pubblicazionePubblicato - 2014

All Science Journal Classification (ASJC) codes

  • Biochimica, Genetica, Biologia Molecolare Generali

Keywords

  • PDGF
  • Peripheral medulloepithelioma
  • Target therapy
  • Treatment

Fingerprint

Entra nei temi di ricerca di 'Peripheral medulloepithelioma: A rare tumor with a potential target therapy'. Insieme formano una fingerprint unica.

Cita questo